Pulse BiosciencesPLSE
PLSE
About: Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Employees: 56
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
86% more call options, than puts
Call options by funds: $1.75M | Put options by funds: $941K
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
5% more capital invested
Capital invested by funds: $98.6M [Q3] → $104M (+$5.16M) [Q4]
0.5% more ownership
Funds ownership: 9.18% [Q3] → 9.68% (+0.5%) [Q4]
0% more funds holding
Funds holding: 72 [Q3] → 72 (+0) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for PLSE.
Financial journalist opinion
Based on 3 articles about PLSE published over the past 30 days
Neutral
Business Wire
1 day ago
Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the upcoming TD Cowen 45th Annual Health Care Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, March 5, 2025, at 10:30 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of.
Neutral
Business Wire
2 weeks ago
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. “I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled.
Neutral
Business Wire
3 weeks ago
Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that its nanosecond PFA Percutaneous Electrode System will be featured in a clinical science session and a video session at the North American Society for Interventional Thyroidology Annual Meeting, being held January 31 through February 1, 2025 in Washington D.C. “To obtain our initial FDA 510(k).
Neutral
Business Wire
1 month ago
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System first-in-human feasibility study, which data were recently presented at the 30th Annual AF Symposium 2025 meeting. The feasibility study is intended to assess the initial safety and efficacy of the Nanosecond PFA 360° Cardiac Catheter System.
Neutral
Business Wire
1 month ago
Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case transmission featuring the nsPFA 360° catheter mapped with the Abbott Ensite X 3D Mapping System at the 30th Annual AF Symposium 2025 meeting, being held January 16-18 in Boston, Massachusetts. “Since joining the Company's.
Neutral
Business Wire
1 month ago
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. "We are thrilled to have Paul assume the role of Chief Executive Officer," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "Having worked very clo.
Neutral
Business Wire
1 month ago
Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Pulse Biosciences' Management is scheduled to present on Wednesday, January 15, 2025, at 3:45 pm PT. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations.
Neutral
Business Wire
1 month ago
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about December 27, 2024, to redeem the first tranche of common stock warrants, redeemable by the Company if the Company's stock trading price exceeds $16.50 for twenty consecutive trading days, that were issued as part of its.
Neutral
Business Wire
2 months ago
Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that, on December 18, 2024, the Company's Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants he acquired in the Company's 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of Co.
Neutral
Business Wire
2 months ago
Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a new publication in the Journal of Thoracic and Cardiovascular Surgery. This preclinical study demonstrates the advantages of the nano-PFA Cardiac Surgical System over radiofrequency technology for the ablation of cardiac tissue. The study was designed to demonstrate the safety and efficacy of a new nan.
Charts implemented using Lightweight Charts™